NEW YORK (GenomeWeb News) – Abbott reported this morning that its first-quarter molecular diagnostics sales increased around 1 percent year over year, while its overall diagnostics revenues climbed a little more than 4 percent.

The pharmaceuticals, diagnostics, and medical devices firm had total revenues of $5.38 billion, up 2 percent from $5.28 billion for the first quarter of 2012. Sales for its diagnostics business, overall, were $1.09 billion.